Gesellschaftsrecht / M&A

Steuern

IP / IT

Windward Bio_we_640x140

Homburger News

Homburger and Windward Bio

On January 10, 2025, Windward Bio Group AG, a Swiss-based private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, announced its launch with a USD 200 m series A financing from lead investors OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and co-investors SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners. Windward Bio has entered into an agreement to license WIN378, a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP), from Kelun-Biotech and Harbour BioMed for global rights, excepting China and select smaller markets in Asia.
Proceeds from the financing will be used to develop a phase 2-ready, long-acting anti-TSLP antibody with best-in-class potential in asthma and chronic obstructive pulmonary disease (COPD).
Homburger AG advises Windward Bio on its set-up and financing. The Homburger team comprises Andreas Müller, Margrit Marti, Oliver Kneubühl, Kaiyan Yeo, Eric Huber, Jonas Stähli, Rebecca Sigrist and Carolina Rodriguez (all Corporate / M&amp;A), Stefan Oesterhelt and Juliette Buob (both Tax) and Luca Dal Molin (IP / IT).

Homburger advises Windward Bio on its USD 200 m Series A Financing

Kapitalmarkt

Wettbewerb

Finanzmarktrecht

20240706_EQT-Galderma

On August 5, 2024, L&#8217;Oréal and Galderma announced the acquisition of a 10% stake in Galderma Group AG from Sunshine SwissCo AG (a consortium led by EQT), Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd. (all acting as sellers), for a non-disclosed amount. In connection therewith, L&#8217;Oréal has agreed vis-à-vis Sunshine SwissCo AG to certain undertakings as part of a shareholders&#8216; agreement. Following the transaction, no changes to the Galderma board of directors and its governance are envisioned.
In addition, L&#8217;Oréal and Galderma have agreed to work towards a strategic scientific partnership that will leverage the undisputed expertise of both companies: Galderma&#8217;s across a broad range of dermatological solutions, and L&#8217;Oréal’s expertise in skin biology, diagnostic tools and evaluation methods.
Homburger acted as transaction counsel to EQT. The team was led by Frank Gerhard and Margrit Marti (both Corporate / M&amp;A, Capital Markets) and comprises Estelle Piccard, Simone Schmid and Héloïse de Jamblinne (all Corporate / M&amp;A), Stefan Oesterhelt (Tax), Richard Stäuber (Competition) as well as Micha Fankhauser (Financial Market Regulation).

Homburger advises EQT on its sale of 10% in Galderma to L'Oréal

Blume Equity_web_640x140

Share-Image Teamplate Deals-and-Cases

On June 25, 2024, Neustark AG (neustark), a Switzerland-based carbon removal provider, announced that it has raised a USD 69 m in funding to expand carbon removal solution globally. The growth equity round was led by Decarbonization Partners, a partnership between BlackRock and Temasek, and will reinforce neustark’s continued growth path and support their mission to permanently remove 1 million tons of CO2 in the year 2030. Climate tech growth investor Blume Equity also participated in the round.
The investment in neustark is one of the largest growth equity investment rounds in carbon removal and was backed by the existing investors Siemens Financial Services, Verve Ventures, ACE Ventures and Holcim. It is intended to propel neustark&#8217;s expansion across Europe, North America and Asia-Pacific.
Homburger acted as legal advisor to Blume Equity in connection with the transaction.
The Homburger team was led by Daniel Hasler (Corporate / M&amp;A) and included Margrit Marti and Jasmin Künzle (all Corporate / M&amp;A).

Margrit
Marti

Homburger advises Windward Bio on its USD 200 m Series A Financing

Homburger advises EQT on its sale of 10% in Galderma to L'Oréal

Homburger advised Blume Equity LLP on its Investment in Neustark AG

Private Equity 2024: Switzerland

Nutzbarmachung des neuen Aktienrechts für Private Equity und Venture Capital

Swiss Corporation Law: A Primer for Legal Practitioners

Join the Team

Margrit Marti

Karriere

Sprachen

Zulassung

Teams

MargritMarti

Homburger advises Windward Bio on its USD 200 m Series A Financing

Homburger advises EQT on its sale of 10% in Galderma to L'Oréal

Homburger advised Blume Equity LLP on its Investment in Neustark AG

Private Equity 2024: Switzerland

Nutzbarmachung des neuen Aktienrechts für Private Equity und Venture Capital

Swiss Corporation Law: A Primer for Legal Practitioners

Join the Team

Margrit Marti

Karriere

Sprachen

Zulassung

Teams

Margrit
Marti